HNF4A and metabolic syndrome: The data strongly support a beneficial role of BBR in improving glucose and lipid homeostasis and suggest that the HNF-4α regulated miR122 pathway is a potential therapeutic target for treatment of T2D with accompanying dyslipidemia.